Work

TATTON expansion cohorts: A phase Ib study of osimertinib plus savolitinib in patients (pts) with EGFR-mutant, MET-positive NSCLC following disease progression on a prior EGFR-TKI

Year: 2019

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdz446.001

Authors: J.-Y. Han, L.V. Sequist, M.-J. Ahn, B.C. Cho, H. Yu, S.-W. Kim, J.C.-H. Yang, J.S. Lee, W.-C. Su, D. Kowalski, S. Orlov, M. Cantarini, R.B. Verheijen, A. Mellemgaard, P. Frewer, X. Ou, G. Oxnard

Institutions: National Cancer Center, Massachusetts General Hospital, Samsung Medical Center, Yonsei University, Yonsei University Health System, Yonsei Cancer Hospital, Memorial Sloan Kettering Cancer Center, Asan Medical Center, University of Ulsan, National Taiwan University Hospital, Seoul National University Bundang Hospital, National Cheng Kung University Hospital, The Maria Sklodowska-Curie National Research Institute of Oncology, AstraZeneca (United Kingdom), Dana-Farber Cancer Institute

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2991637555

FWCI: 0.165

Cites:

Cited by: 1

Related to: 10